SavedAdd your journal

Journals / Üroonkoloji Bülteni / 2020 / Cilt: 19 - Sayı: 4

Efficacy of Chemotherapy Combinations in Metastatic Castration-Resistant Prostate Cancer Patients - Do Homologous Recombination Deficiency Affect the Outcomes?

Emre YEKEDÜZ
Güngör UTKAN
YÜKSEL ÜRÜN
Pages
175–176
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Additionally, the combination of cabazitaxel and carboplatin led to increased toxicity.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Homologous recombination (HR) is a major repair mechanism of DNA damage.
📊
Key Findings & Data:Furthermore, prostate cancers with a higher rate of small cell or anaplastic carcinoma components are more susceptible to carboplatin plus etoposide.
💡
Conclusion & Impact:Additionally, the combination of cabazitaxel and carboplatin led to increased toxicity.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Özet

Homologous recombination (HR) is a major repair mechanism of DNA damage. Platin-based agents are known to be more effective in patients with impaired HR mechanism. Previous studies combined platin compounds with docetaxel, but most of these studies did not perform subgroup analysis for HR-deficient patients. Aggressive variant prostate cancer (AVPC) is considered more susceptible to carboplatin. Furthermore, prostate cancers with a higher rate of small cell or anaplastic carcinoma components are more susceptible to carboplatin plus etoposide. We thought that the effect of cabazitaxel plus carboplatin on the progression-free survival might be related to carboplatin alone. In a study that evaluated the effect of cabazitaxel plus carboplatin, the proportion of AVPC patients was higher in the combination group than in the cabazitaxel group. Additionally, the combination of cabazitaxel and carboplatin led to increased toxicity.

🔖

Cite This Article

YEKEDÜZ, E., UTKAN, G., ÜRÜN, Y. (2020). Efficacy of Chemotherapy Combinations in Metastatic Castration-Resistant Prostate Cancer Patients - Do Homologous Recombination Deficiency Affect the Outcomes?. Üroonkoloji Bülteni, Cilt: 19 - Sayı: 4, 175–176. https://ajindex.com/articles/334452

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (13)

  1. Eisenberger M, Hardy-Bessard AC, Kim CS, et al. Phase III Study Comparing a Reduced Dose of Cabazitaxel (20 mg/m(2)) and the Currently Approved Dose (25 mg/m(2)) in Postdocetaxel Patients With Metastatic Castration-Resistant Prostate Cancer-PROSELICA. J Clin Oncol 2017;35:3198-3206
  2. Tannock IF, de Wit R, Berry WR, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004;351:1502-1512
  3. Christenson ES, Antonarakis ES. PARP inhibitors for homologous recombination-deficient prostate cancer. Expert Opin Emerg Drugs 2018;23:123-133
  4. Oh M, Alkhushaym N, Fallatah S, et al. The association of BRCA1 and BRCA2 mutations with prostate cancer risk, frequency, and mortality: A meta-analysis. Prostate 2019;79:880-895
  5. Nombela P, Lozano R, Aytes A, et al. BRCA2 and Other DDR Genes in Prostate Cancer. Cancers (Basel) 2019;11:352
  6. Pomerantz MM, Spisak S, Jia L, et al. The association between germline BRCA2 variants and sensitivity to platinum-based chemotherapy among men with metastatic prostate cancer. Cancer 2017;123:3532-3539
  7. Tsaur I, Heidegger I, Kretschmer A, et al. Aggressive variants of prostate cancer - Are we ready to apply specific treatment right now? Cancer Treat Rev 2019;75:20-26
  8. Tryggvadottir L, Vidarsdottir L, Thorgeirsson T, et al. Prostate cancer progression and survival in BRCA2 mutation carriers. J Natl Cancer Inst 2007;99:929-935
  9. Chedgy EC, Vandekerkhove G, Herberts C, et al. Biallelic tumour suppressor loss and DNA repair defects in de novo small-cell prostate carcinoma. J Pathol 2018;246:244-253
  10. Beltran H, Tomlins S, Aparicio A, et al. Aggressive variants of castrationresistant prostate cancer. Clin Cancer Res 2014;20:2846-2850
  11. Aparicio AM, Harzstark AL, Corn PG, et al. Platinum-based chemotherapy for variant castrate-resistant prostate cancer. Clin Cancer Res 2013;19:3621-3630
  12. Bumbaca B, Li W. Taxane resistance in castration-resistant prostate cancer: mechanisms and therapeutic strategies. Acta Pharm Sin B 2018;8:518-529
  13. Corn PG, Heath EI, Zurita A, et al. Cabazitaxel plus carboplatin for the treatment of men with metastatic castration-resistant prostate cancers: a randomised, open-label, phase 1-2 trial. Lancet Oncol 2019;20:1432-1443.